Vitamin D levels before starting treatment were tied to subsequent multiple sclerosis (MS) disease activity. (Journal of Neurology, Neurosurgery, and Psychiatry)
Several brands of nootropic gummies containing mushrooms, marketed to enhance cognitive function, contained undisclosed psilocybin and psilocin. (Morbidity and Mortality Weekly Report)
Researchers showed how psilocybin desynchronized neural networks and changed communication pathways connecting brain regions. (Nature)
Two top officials at Cassava Sciences resigned after a federal grand jury filed fraud charges against a research collaborator. The company’s investigational drug for Alzheimer’s, simufilam, is in phase III trials. (New York Times)
Researchers launched a new platform to share de-identified study data from the A4 study of pre-symptomatic Alzheimer’s disease, the Keck School of Medicine of USC said.
Ofatumumab (Kesimpta) was more effective than teriflunomide (Aubagio) at helping relapsing MS patients in racial/ethnic subgroups reach three-parameter no evidence of disease activity (NEDA-3), a post hoc analysis showed. (Neurology)
Functional connectivity of hippocampal networks could forecast epileptic seizures. (Nature Medicine)
Uninsured and Hispanic people were less likely to be referred to post-acute stroke care facilities in 2017-2018, National Inpatient Sample data showed. (Neurology Clinical Practice)
A machine-learning model identified three subtypes of Parkinson’s disease, each with distinct progression patterns. (NPJ Digital Medicine)
Please enable JavaScript to view the